CA-TRADESHIFT
10.2.2020 15:02:12 CET | Business Wire | Press release
Tradeshift, the leader in supply chain payments and marketplaces, has announced the addition of four new hires hailing from Microsoft, Ariba, SAP and Oracle. On the heels of Tradeshift’s latest funding news, in which the company announced $240 million in funding, the company welcomes these seasoned veterans to help the company reach its strategic goals for 2020.
The four new hires represent deep experience in a range of business leadership initiatives including network, product and sales. The roles include:
Janet Heppner-Jones, VP of North America Sales : Heppner-Jones has an impressive background in digital solutions and SaaS sales leadership, most recently leading the America's sales team at Baker Hughes. Her diverse background has provided her with global executive responsibilities in many multinational companies across many business functions, including SAP, ABB, Dassault Systems, and Ariba. Heppner-Jones began her career as a Sales Representative with IBM where she earned the prestigious Eagle Award (top 1% of the sales force). At Tradeshift, Heppner-Jones will continue and accelerate the 60 percent growth rate, increase deal size, and work with partners in North America.
Tony Alvarez, VP of Network : Alvarez will be responsible for Tradeshift seller onboarding, GMV growth, and the Tradeshift early payment and Marketplace offerings. Prior to joining, Alvarez spent 10 years with SAP Ariba serving in several senior leadership positions in the commercial and operational functions, most recently serving as SVP of Ariba Business Network Solutions. He has experience in large deal negotiations, network monetization, and marketplace development. Alvarez began his career with Arthur Andersen Consulting, then went on to earn his MBA at Harvard.
Henry Goh, VP of APAC Sales: Goh will be leading all APAC sales as the VP of Sales, APAC. For the past 10 years, Goh has been running APAC sales for Ariba. Prior to Ariba, he was at PwC and Oracle leading teams across Asia. Goh has a wealth of experience in “go-to-market” strategy in APAC. He has experience in large deal negotiations including cultivating, developing, formulating and constructing deals.
Raphael Bres, Chief Product Officer: Bres brings to Tradeshift over 20 years experience building ERP’s at Workday, FinancialForce, and Peoplesoft, built on a solid foundation from Deloitte, Oracle and Microsoft. While Bres will be based out of our San Francisco office, he also brings strong global experience, having not only held international roles but also earning his graduate degrees from Université Paris Dauphine.
“This is a pivotal year for Tradeshift and we’re hyper-focused on the areas of the business that will give us the greatest momentum and lead us to profitability,” said Christian Lanng, CEO of Tradeshift. “With a combined 70 years of experience, Janet, Tony, Henry and Raphael will successfully lead the charge on tackling the aggressive and ambitious goals we have set out for ourselves and will no doubt make this the most successful year we’ve seen at Tradeshift.”
About Tradeshift
Tradeshift drives supply chain innovation for the digitally connected economy. As the leader in supply chain payments and marketplaces, the company helps buyers and suppliers digitize all their trade transactions, collaborate on every process, and connect with any supply chain app. More than 1.5 million companies across 190 countries trust Tradeshift to process over half a trillion USD in transaction value, making it the largest global business network for buying and selling. Discover commerce for all at tradeshift.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom